Cargando…

Modulating native GABA(A) receptors in medulloblastoma with positive allosteric benzodiazepine-derivatives induces cell death

PURPOSE: Pediatric brain cancer medulloblastoma (MB) standard-of-care results in numerous comorbidities. MB is comprised of distinct molecular subgroups. Group 3 molecular subgroup patients have the highest relapse rates and after standard-of-care have a 20% survival. Group 3 tumors have high expres...

Descripción completa

Detalles Bibliográficos
Autores principales: Kallay, Laura, Keskin, Havva, Ross, Alexandra, Rupji, Manali, Moody, Olivia A., Wang, Xin, Li, Guanguan, Ahmed, Taukir, Rashid, Farjana, Stephen, Michael Rajesh, Cottrill, Kirsten A., Nuckols, T. Austin, Xu, Maxwell, Martinson, Deborah E., Tranghese, Frank, Pei, Yanxin, Cook, James M., Kowalski, Jeanne, Taylor, Michael D., Jenkins, Andrew, Pomeranz Krummel, Daniel A., Sengupta, Soma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478651/
https://www.ncbi.nlm.nih.gov/pubmed/30725256
http://dx.doi.org/10.1007/s11060-019-03115-0
Descripción
Sumario:PURPOSE: Pediatric brain cancer medulloblastoma (MB) standard-of-care results in numerous comorbidities. MB is comprised of distinct molecular subgroups. Group 3 molecular subgroup patients have the highest relapse rates and after standard-of-care have a 20% survival. Group 3 tumors have high expression of GABRA5, which codes for the α5 subunit of the γ-aminobutyric acid type A receptor (GABA(A)R). We are advancing a therapeutic approach for group 3 based on GABA(A)R modulation using benzodiazepine-derivatives. METHODS: We performed analysis of GABR and MYC expression in MB tumors and used molecular, cell biological, and whole-cell electrophysiology approaches to establish presence of a functional ‘druggable’ GABA(A)R in group 3 cells. RESULTS: Analysis of expression of 763 MB tumors reveals that group 3 tumors share high subgroup-specific and correlative expression of GABR genes, which code for GABA(A)R subunits α5, β3 and γ2 and 3. There are ~ 1000 functional α5-GABA(A)Rs per group 3 patient-derived cell that mediate a basal chloride-anion efflux of 2 × 10(9) ions/s. Benzodiazepines, designed to prefer α5-GABA(A)R, impair group 3 cell viability by enhancing chloride-anion efflux with subtle changes in their structure having significant impact on potency. A potent, non-toxic benzodiazepine (‘KRM-II-08’) binds to the α5-GABA(A)R (0.8 µM EC(50)) enhancing a chloride-anion efflux that induces mitochondrial membrane depolarization and in response, TP53 upregulation and p53, constitutively phosphorylated at S392, cytoplasmic localization. This correlates with pro-apoptotic Bcl-2-associated death promoter protein localization. CONCLUSION: GABRA5 expression can serve as a diagnostic biomarker for group 3 tumors, while α5-GABA(A)R is a therapeutic target for benzodiazepine binding, enhancing an ion imbalance that induces apoptosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11060-019-03115-0) contains supplementary material, which is available to authorized users.